SlideShare una empresa de Scribd logo
1 de 40
Descargar para leer sin conexión
SCHEDULE Y
Presented by-
DEBASHIS DAS
M.Pharm 1st Sem
RIPANS
 Objective…
 What actually schedule Y is?
 Why changes in schedule Y?
 Rules under schedule Y…
 Appendices of schedule Y…
 Conclusion
 references
 The main objectives of the drugs and
cosmetic acts 1940, is to regulate the import,
manufacture, distribution and sale of drugs &
cosmetics in the country
 It also ensure that the drugs that are available
to the people are safe and efficacious and the
cosmetics marketed are safe for use
Schedule Y
It’s a law
Not merely a
Guideline
 Schedule Y ,the current regulator (of CDSCO), enforced
law in India has been established under Drug and
Cosmetic Act,1945.
 The regulations to be followed when conducting
Clinical Trial.
 Schedule Y – requirements and guidelines for
permission to import and/or manufacture of new drugs
for sale or to undertake clinical trial
 Date 20 January, 2005
 To frame guidelines for the current scenario of Clinical
research.
 CDSCO and DTAB formulated GCP under Schedule Y in 2005.
 Schedule Y 1988 relevant to predominantly generic industry.
 GCP trials since 1995, and arrival of IPR regime in 2005.
 Integration of India in global clinical development and legal
support to GCP guidelines.
 Improvements in quality of clinical trials.
 It has outlined extensive study criteria in line with the
globally accepted formats such as ICH and US FDA guidelines
 122A - Application for permission to import new drug
 122 B - Application for approval to manufacture new drug
 122 D -Permission to import or manufacture FDC
 122 DA- Permission to conduct clinical trials for New Drug /
Investigational New Drug
 122 DAA –Definition Of “CLINICAL TRIAL”
 “Clinical trial” - a systematic study of new drug(s) in human
subject(s) to generate data for discovering and / or verifying
the clinical, pharmacological effect (including
pharmacodynamic and pharmacokinetic) and /or adverse
effects with the objective of determining safety and / or
efficacy of the new drug.
122-E
Definition of new drugs
Not been used in the country under labeling
conditions
Approved but now proposed to be marketed with
modified or new claims – indications, dosage, dosage
form , route of administration , FDC , individually
approved to be combined for the first time in a fixed
ratio or if ratio is changed
APPENDICES of schedule y
It contains data to be submitted along with the application to
conduct clinical trials / import / manufacture of new drugs for
marketing in the country.
1. Introduction
• a. A brief description of the drug and
the therapeutic class to which it belongs.
2. Chemical and pharmaceutical information
• 2.1 Information on active ingredients
Drug information (Generic Name, Chemical Name etc.)
Physicochemical Data
A. Chemical name and Structure
Empirical formula
Molecular weight
B. Physical properties
Solubility
Rotation
Partition coefficient
Dissociation constant
2.3 Analytical Data
Elemental analysis
Mass spectrum
NMR spectra
IR spectra
UV spectra
Polymorphic identification
2.4 Complete monograph specification including
Identification
Identity/quantification of impurities
Enantiomeric purity
Assay
2.5 validation
2.6 stability studies ( for details refer appendix IX)
3.Animal pharmacology
(for details refer appendix IV)
 Summary
 Specific pharmacological actions
 General pharmacological actions
 Follow-up and Supplemental Safety Pharmacology Studies
 Pharmacokinetics: absorption, distribution; metabolism;
excretion
2.7 data on formulation
• dosage form,
•composition,
•master manufacturing formula,
•In process quality control check,
•Excipients compatibility study
•Finished product specification
•Validation of the analytical method
4. Animal toxicology (for detail refer appendix IV)
General Aspects
Systemic Toxicity Studies
Male Fertility Study
Female Reproduction and Developmental Toxicity
Studies
Local toxicity
Allergenicity/Hypersensitivity
Genotoxicity
Carcinogenicity
5. Human/clinical pharmacology (phase I)
•Summary
•Specific Pharmacological effects
•General Pharmacological effects
•Pharmacokinetics, absorption, distribution,
metabolism, excretion
•Pharmacodynamics /early measurement of
drug activity
6. Therapeutic exploratory trial (phase II)
•Summary
•Study report(s) as given in Appendix II
7. Therapeutic confirmatory trial (phase III)
•Summary
•Individual study reports with listing of sites
and Investigators.
8. Special studies
Summary
Bio-availability / Bio-equivalence.
Study on special group of population e.g. geriatrics, pediatrics ,
pregnant or nursing women
Geriatrics
•Geriatric patients should be included in Phase III clinical trials (and in
Phase II trials, at the Sponsor's option) in meaningful numbers,
•If the disease intended to be treated is characteristically a disease of
aging; or
the population to be treated is known to include substantial
numbers of geriatric patients;
The pediatric studies should include -
clinical trials,
relative bioequivalence comparisons of the pediatric formulation
with the adult formulation performed in adults
definitive pharmacokinetic studies for dose selection across the age
ranges of pediatric patients in whom the drug is likely to be used.
These studies should be conducted in the pediatric patient population
with the disease under study
The timing of pediatric studies in the new drug development
program will depend on the medicinal product, the type of disease
being treated, safety considerations, and the efficacy and safety of
available treatments.
Pediatrics
Pregnant or Nursing Women
•Pregnant or nursing women should be included
in clinical trials only when the drug is intended for use by
pregnant/nursing women or fetuses/nursing infants and
where the data generated from women who are not pregnant or
nursing, is not suitable.
•For new drugs intended for use during pregnancy, follow-up data
(pertaining to a period appropriate for that drug) on the pregnancy,
fetus and child will be required.
9. Regulatory status in other countries
9.1 countries where the drug is
a. marketed
b. Approved
c. approved as IND
d. withdrawn, if any , with reason
9.2 restriction use, if any , in countries where marketed/ approved
9.3 free sale certificate or certificate of analysis , as appropriate.
10. Prescribing information
10.1 proposed full prescribing information
11. Samples and testing protocol
NOTE : All items may not be applicable to all drugs. For
explanation, refer text of Schedule Y.
•For requirements of data to be submitted with application for
clinical trials we should refer text of this Schedule
 Data required to be submitted by an applicant for grant of
permission to import and/or manufacture a new drug already
approved in the country
 Introduction ( About the drug and its therapeutic class)
 Chemical and pharmaceutical information (Chemical name, Generic
name, Structure , Physico chemical properties)
 Marketing information (Promotional literature)
 Special studies conducted with approval of licensing authority
◦ Bioavailability/ Bioequivalance and comparative dissolution
studies for oral dosage forms
◦ Sub acute animal toxicity studies for intravenous infusions and
injectables.
 1. Title page :- title of the study, the protocol code,
name of the investigational product tested,
development phase, indication studied, a brief
description page, the start and end date of patient
accrual and the names of the sponsor and the
participating institute
 2. Study synopsis(1 to 2 pages) :- a brief review of
study from the protocol development to the trial closure
should be given here. This section will only summarize
the important conclusions derived from the study
 3. statement of compliance
 4.list of abbreviation and definitions
 Table of contents
 6. ethics committee:
 7.study team
 8.study objective
 9.investigational plan
 Trial subjects
 Efficacy evaluation
 Safety evaluation
 Discussion and overall conclusion
 List of references
 appendices
ANIMAL TOXICOLOGY (NON-CLINICAL TOXICITY STUDIES)
• Acute toxicity
• Long-term toxicity
 Reproduction studies
• Fertility studies
• Teratogenicity studies:
 Local toxicity:
 Mutagenicity and Carcinogenicity
 Application Of Good Laboratory Practices (GLP)
Animal pharmacology
 General Principles
◦ Specific and general pharmacological studies should be
conducted to support the use of therapeutics in human
◦ Safety pharmacological studies investigates potential undesirable
pharmacodynamic effect of as substance on physiological
function in relation to exposer within the therapeutic range or
above.
 Specific Pharmacological Actions
 Are those which demonstrate the therapeutic potential for humans.
 General pharmacological Actions
 Essential Safety Pharmacology
 To study the effect of the test drug on vital functions such as
cardiovascular, respiratory and central nervous system are
studied
 Supplemental Safety Pharmacology Studies
Investigation of the adverse pharmacological effect that are not
assessed in the in the essential safety pharmacological studies
and are a cause for concern
 Urinary System
Includes urine volume, specific gravity , osmolality, pH ,
proteins, cytology, and blood urea nitrogen , creatinine ,
plasma protein estimation .
 Autonomic Nervous System
Binding to receptor relevant to ANS and functional response
to agonist or antagonist responses in in vitro or in vivo.
 Gastrointestinal System
Studies of gastric secretion, gastric pH, bile secretion,
gastric emptying time etc
Other Organ Systems
 Trial involves research
 Purpose
 Trial treatment and randomization
 Trial procedures
 Risk
 Benefit
 Alternative treatments
 Compensation /treatment for injury
 Subject responsibilities
 Experiment aspects
 Any payment
 Confidentiality
 New information
 Voluntary participation
 Persons to contact for study information
 Rights of subjects, if study related injury
 Reasons for termination
 Duration of study
 Number of subjects
 Any other pertinent information
 Study title
 Subject initials e.g. subjects name/date of
birth/age
 Consent statement with initials in
 A) signature of the subject
 B) Legally acceptable representative
 Signature of the investigator
 Study investigators name
 Signature of the witness
 Name of the witness
Combination therapy with two or more agents having complementary
mechanism of action is an example of incremental innovation
that may extend the range of therapeutic options in the
treatment of almost every human disease
Fixed dose combination(FDC) fall into four categories
A. one or more of the active ingredients is a new drugs
B. First time combination of individually approved/marketed drugs,
where the ingredients are likely to have significant interaction of
a pharmacodynamic or pharmacokinetic nature
C. Combination already marketed, but in which it is proposed either
to change the ratio of active ingredients or to make new
therapeutic claim
D. Combined only for the purpose of convenience
1. - Full name
- Address
- Title of Principal Investigator (or Investigator if no PI)
2. -Name & Address of the medical college, hospital or facility.
- Education training & experience of the Investigator
3. Name & address of all clinical laboratory facilities
4. Name and address of EC
5. Name of other members of the research team
6. Protocol title & Study number (if any)
7. Commitments
8. Signature of the Investigator with Date.
Appendix VIII - ETHICS COMMITTEE
•It should have at least seven members .
• a chair person (who is from outside the institution) and a
member secretary
•Other member should be mix of medical/ non-medical
scientific/ non-scientific persons including lay public , to
reflect their different view point
•The quorum of ethics committee should have at least 5
members
•Basic medical scientist( pharmacologist)
•Clinician
•Legal expert
•Social scientist/ethicist/philosopher etc.
•Lay person from the community
NOTE : ONLY THOSE ETHICS COMMITTEE MEMBER WHO ARE INDEPENDENT OF THE
CLINICAL TRIAL AND THE SPONSOR OF THE TRIAL SHOULD VOTE / PROVIDE OPINION IN
MATTERS RELATED TO STUDY .
 Stability testing is to be performed to provide evidence on how the
quality of the drug substance or formulation varies with time under
influence of environmental factors such as temperature , humidity ,
and light , and to establish shelf life for the formulation and
recommended storage condition
 It includes testing of those attributes of the drug that are susceptible to
change during storage and are likely to influence quality , safety and /
or efficacy .
 Title page
◦ Full title of the clinical study
◦ Protocol/study number and protocol version number with date
◦ The Investigational New Drug (IND) name/number of the
investigational drugs
◦ Complete name and address of the sponsor and contract research
organization if any
◦ List of the investigators who are conducting the study
◦ Names of clinical laboratories and other departments and/ or facilities
participating in the studies
 Table of content
◦ A complete table of content including a list of all appendices
1. Background and Introduction
a. Preclinical experiences
b. Clinical experiences
2 . Study rationale
This section should describe a brief summary of the background
information relevant to the study design and protocol
methodology
3. Study design
a. Overview of the study design
b. Flowchart of the study
c. A brief description of the methods and procedure used during
the study
4. Study population
the number of subject required to be enrolled in the study at the
investigative site and by all site along with a brief description of
the nature of the subject population required is also mentioned
5.Subject eligibility
a. Inclusion criteria
b. Exclusion criteria
6. Study treatment:
Dosing schedule , details of product stability, storage
requirements , dispensing requirements, possible drug
interactions
7. Adverse events: Description of expected adverse events should be
given
8. Data analysis
9. Undertaking by the investigator (appendix VII)
NOTE- protocol is assigned by sponsor after getting CDA from
investigator
1. Patient details
 Initials & other relevant identifier (hospital/ OPD record number etc)
 Gender
 Age &/or date of birth
 Weight
 Height
2. Suspected drug(s)
- Generic name of the drug
- Indication(s) for which suspect drug was prescribed or tested
- Dosage form and strength
- Daily dose & regimen (specify units-e.g. mg, ml, mg/kg)
- Route of administration
- Starting date & time of the day
- Stopping date and time, or duration of treatment
3. Details of suspected Adverse Drug Reaction(s)
 Full Description of reaction(s) including:
- body site
- severity
- criterion for considering the
report as serious.
 In addition to the description of signs & symptoms whenever possible
describe a specific diagnosis for the reaction.
- Start date (& time) of onset of reaction
- Stop date (& time) of duration of reaction
4. Details about Investigator
- Name
- Address
- Telephone number
- Profession (Specialty)
- Date of reporting the event to the Licensing Authority
- Date of reporting the event to Ethics Committee over seeing the site
- Signature of the Investigator
“With The Schedule Y The Efforts Are
Aligned In a Single Direction To Ensure
That Irrespective Of The Country, The
Data Generated is Of Good Quality And
Standard Which Can Be Accepted
World Wide”
1. GUPTA S. K. BASIC PRINCIPLE OF CLINICAL RESEARCH AND
METHODOLOGY
2. http://www.slideshare.net/slideshare006/schedule-y-mk-
sharma.(date-08.12.2016)
3. http://www.cdsco.nic.in/html/D&C_Rules_Schedule_Y.pdf(11.1
2.2016)
schedule y of drugs and cosmetic acts

Más contenido relacionado

La actualidad más candente

WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramSnehaKhandale1
 
Medical Dictionary for Regulatory Activities (MedDRA)
Medical Dictionary for Regulatory Activities (MedDRA)Medical Dictionary for Regulatory Activities (MedDRA)
Medical Dictionary for Regulatory Activities (MedDRA)SMS MEDICAL COLLEGE
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRama Shukla
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...Audumbar Mali
 
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)Vijay Banwala
 
Severity, seriousness, predictability and preventability assessment
Severity, seriousness, predictability and preventability assessmentSeverity, seriousness, predictability and preventability assessment
Severity, seriousness, predictability and preventability assessmentDr. Ramesh Bhandari
 
Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]Sagar Savale
 
ICH safety guidelines
ICH safety guidelinesICH safety guidelines
ICH safety guidelinesvishnu Jatoth
 
History and progress of pharmacovigilance
History and progress of pharmacovigilanceHistory and progress of pharmacovigilance
History and progress of pharmacovigilanceGagandeep Jaiswal
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.Audumbar Mali
 
Standardized and MedDRA Queries
Standardized and MedDRA QueriesStandardized and MedDRA Queries
Standardized and MedDRA QueriesRajat Garg
 
Clinical trials & phases of clinical trials
Clinical trials & phases of clinical trialsClinical trials & phases of clinical trials
Clinical trials & phases of clinical trialsDr. Vijay Kumar Pathak
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceMd. Zakaria Faruki
 
Drug regulatory authority
Drug regulatory authority Drug regulatory authority
Drug regulatory authority Rahul Gawande
 

La actualidad más candente (20)

WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring Program
 
CDSCO- CENTRAL DRUG STANDARD CONTROL ORGANISATION
CDSCO- CENTRAL DRUG STANDARD CONTROL ORGANISATIONCDSCO- CENTRAL DRUG STANDARD CONTROL ORGANISATION
CDSCO- CENTRAL DRUG STANDARD CONTROL ORGANISATION
 
Medical Dictionary for Regulatory Activities (MedDRA)
Medical Dictionary for Regulatory Activities (MedDRA)Medical Dictionary for Regulatory Activities (MedDRA)
Medical Dictionary for Regulatory Activities (MedDRA)
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical Industry
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
 
Schedule y
Schedule  ySchedule  y
Schedule y
 
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
Severity, seriousness, predictability and preventability assessment
Severity, seriousness, predictability and preventability assessmentSeverity, seriousness, predictability and preventability assessment
Severity, seriousness, predictability and preventability assessment
 
Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]
 
ICH safety guidelines
ICH safety guidelinesICH safety guidelines
ICH safety guidelines
 
History and progress of pharmacovigilance
History and progress of pharmacovigilanceHistory and progress of pharmacovigilance
History and progress of pharmacovigilance
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.
 
Standardized and MedDRA Queries
Standardized and MedDRA QueriesStandardized and MedDRA Queries
Standardized and MedDRA Queries
 
Clinical trials & phases of clinical trials
Clinical trials & phases of clinical trialsClinical trials & phases of clinical trials
Clinical trials & phases of clinical trials
 
CONTRACT RESEARCH ORGANIZATION
CONTRACT RESEARCH ORGANIZATIONCONTRACT RESEARCH ORGANIZATION
CONTRACT RESEARCH ORGANIZATION
 
CIOMS (1).pptx
CIOMS (1).pptxCIOMS (1).pptx
CIOMS (1).pptx
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and Pharmacovigilance
 
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’SSEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
 
Drug regulatory authority
Drug regulatory authority Drug regulatory authority
Drug regulatory authority
 

Destacado

Drugs & cosmetics act 1940
Drugs & cosmetics act 1940Drugs & cosmetics act 1940
Drugs & cosmetics act 1940Rakshit Thumar
 
Schedule y under drugs and cosmetic act 1945
Schedule y  under drugs and cosmetic act 1945Schedule y  under drugs and cosmetic act 1945
Schedule y under drugs and cosmetic act 1945neelotpal31
 
recent updates in cosmetic technology
recent updates in cosmetic technologyrecent updates in cosmetic technology
recent updates in cosmetic technologyKhaled Al-Qaoud
 
Class newer routes of drug delivery
Class newer routes of drug deliveryClass newer routes of drug delivery
Class newer routes of drug deliveryRaghu Prasada
 
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...Vigipharm
 
Membrane transporters and drug response
Membrane transporters and drug responseMembrane transporters and drug response
Membrane transporters and drug responseAditi Panditrao
 
Newer drug delivery systems
Newer  drug delivery systemsNewer  drug delivery systems
Newer drug delivery systemsMandeep Sarma
 
Transporters as targets for drugs
Transporters as targets for drugsTransporters as targets for drugs
Transporters as targets for drugsshikha singh
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomicsshabrelhan
 
Medical Devices Postmarket Surveillance 14 jul13
Medical Devices Postmarket Surveillance 14 jul13Medical Devices Postmarket Surveillance 14 jul13
Medical Devices Postmarket Surveillance 14 jul13Annet Visscher
 
Newer drug delivery methods
Newer drug delivery methodsNewer drug delivery methods
Newer drug delivery methodsPrasheeta V P
 

Destacado (20)

Drugs & cosmetics act 1940
Drugs & cosmetics act 1940Drugs & cosmetics act 1940
Drugs & cosmetics act 1940
 
Schedule y, mk sharma
Schedule y, mk sharmaSchedule y, mk sharma
Schedule y, mk sharma
 
Schedule y under drugs and cosmetic act 1945
Schedule y  under drugs and cosmetic act 1945Schedule y  under drugs and cosmetic act 1945
Schedule y under drugs and cosmetic act 1945
 
Schedule Y
Schedule YSchedule Y
Schedule Y
 
sancrae1
sancrae1sancrae1
sancrae1
 
Stability testing for drug products
Stability testing for drug productsStability testing for drug products
Stability testing for drug products
 
Stress and college students
Stress and college studentsStress and college students
Stress and college students
 
recent updates in cosmetic technology
recent updates in cosmetic technologyrecent updates in cosmetic technology
recent updates in cosmetic technology
 
mbbs ims msu
mbbs ims msumbbs ims msu
mbbs ims msu
 
Class newer routes of drug delivery
Class newer routes of drug deliveryClass newer routes of drug delivery
Class newer routes of drug delivery
 
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...
1ères rencontres autour des vigilances sanitaires : Intervention matériovigil...
 
Membrane transporters and drug response
Membrane transporters and drug responseMembrane transporters and drug response
Membrane transporters and drug response
 
Newer drug delivery systems
Newer  drug delivery systemsNewer  drug delivery systems
Newer drug delivery systems
 
Transporters as targets for drugs
Transporters as targets for drugsTransporters as targets for drugs
Transporters as targets for drugs
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
newer drug delivery systems
newer drug delivery systemsnewer drug delivery systems
newer drug delivery systems
 
9 Karin Heidenreich - Novartis
9 Karin Heidenreich -  Novartis9 Karin Heidenreich -  Novartis
9 Karin Heidenreich - Novartis
 
Medical Devices Postmarket Surveillance 14 jul13
Medical Devices Postmarket Surveillance 14 jul13Medical Devices Postmarket Surveillance 14 jul13
Medical Devices Postmarket Surveillance 14 jul13
 
Smart Drug Delivery Systems
Smart Drug Delivery SystemsSmart Drug Delivery Systems
Smart Drug Delivery Systems
 
Newer drug delivery methods
Newer drug delivery methodsNewer drug delivery methods
Newer drug delivery methods
 

Similar a schedule y of drugs and cosmetic acts

Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Saiyad Arsh zia
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and developmentSujith Thokala
 
Scope of pharmacology
Scope of pharmacologyScope of pharmacology
Scope of pharmacologyjireankita
 
Veena Sanjay Katoriya
Veena Sanjay KatoriyaVeena Sanjay Katoriya
Veena Sanjay KatoriyaVEENA18
 
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxPART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxDilsarGohil1
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agenciesUrmila Aswar
 
Schedule Y by akshdeep sharma
Schedule Y by akshdeep sharmaSchedule Y by akshdeep sharma
Schedule Y by akshdeep sharmaAkshdeep Sharma
 
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021University of Gondar
 
Comprehensive pharmacy review
Comprehensive pharmacy reviewComprehensive pharmacy review
Comprehensive pharmacy reviewMaged Kostandy
 
Regulation in clinical trial, Schedule Y and recent amendments
Regulation in clinical trial, Schedule Y and recent amendmentsRegulation in clinical trial, Schedule Y and recent amendments
Regulation in clinical trial, Schedule Y and recent amendmentsDr. Siddhartha Dutta
 
Regulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIRegulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIJafarali Masi
 
INDs: When Required and Contents
INDs: When Required and ContentsINDs: When Required and Contents
INDs: When Required and ContentsLouise666
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 
Drug Development.pptx
Drug Development.pptxDrug Development.pptx
Drug Development.pptxavinakharat
 
Various process of drug development
Various process of drug developmentVarious process of drug development
Various process of drug developmentAyanpal33
 

Similar a schedule y of drugs and cosmetic acts (20)

Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Nda
NdaNda
Nda
 
Schedule y draft 2
Schedule y draft 2Schedule y draft 2
Schedule y draft 2
 
Schedule Y
Schedule YSchedule Y
Schedule Y
 
Scope of pharmacology
Scope of pharmacologyScope of pharmacology
Scope of pharmacology
 
Veena Sanjay Katoriya
Veena Sanjay KatoriyaVeena Sanjay Katoriya
Veena Sanjay Katoriya
 
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxPART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
Schedule Y by akshdeep sharma
Schedule Y by akshdeep sharmaSchedule Y by akshdeep sharma
Schedule Y by akshdeep sharma
 
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021
Ch 1 what is pharmacoepidemiology lec bmeskel for uo g sop pscm yi jan 30 2021
 
Comprehensive pharmacy review
Comprehensive pharmacy reviewComprehensive pharmacy review
Comprehensive pharmacy review
 
Regulation in clinical trial, Schedule Y and recent amendments
Regulation in clinical trial, Schedule Y and recent amendmentsRegulation in clinical trial, Schedule Y and recent amendments
Regulation in clinical trial, Schedule Y and recent amendments
 
Schedule y
Schedule ySchedule y
Schedule y
 
Regulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIRegulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy II
 
INDs: When Required and Contents
INDs: When Required and ContentsINDs: When Required and Contents
INDs: When Required and Contents
 
Schedule Y Summary
Schedule Y SummarySchedule Y Summary
Schedule Y Summary
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
 
Drug Development.pptx
Drug Development.pptxDrug Development.pptx
Drug Development.pptx
 
Various process of drug development
Various process of drug developmentVarious process of drug development
Various process of drug development
 

Último

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 

Último (20)

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 

schedule y of drugs and cosmetic acts

  • 1. SCHEDULE Y Presented by- DEBASHIS DAS M.Pharm 1st Sem RIPANS
  • 2.  Objective…  What actually schedule Y is?  Why changes in schedule Y?  Rules under schedule Y…  Appendices of schedule Y…  Conclusion  references
  • 3.  The main objectives of the drugs and cosmetic acts 1940, is to regulate the import, manufacture, distribution and sale of drugs & cosmetics in the country  It also ensure that the drugs that are available to the people are safe and efficacious and the cosmetics marketed are safe for use
  • 4. Schedule Y It’s a law Not merely a Guideline
  • 5.  Schedule Y ,the current regulator (of CDSCO), enforced law in India has been established under Drug and Cosmetic Act,1945.  The regulations to be followed when conducting Clinical Trial.  Schedule Y – requirements and guidelines for permission to import and/or manufacture of new drugs for sale or to undertake clinical trial  Date 20 January, 2005
  • 6.  To frame guidelines for the current scenario of Clinical research.  CDSCO and DTAB formulated GCP under Schedule Y in 2005.  Schedule Y 1988 relevant to predominantly generic industry.  GCP trials since 1995, and arrival of IPR regime in 2005.  Integration of India in global clinical development and legal support to GCP guidelines.  Improvements in quality of clinical trials.  It has outlined extensive study criteria in line with the globally accepted formats such as ICH and US FDA guidelines
  • 7.  122A - Application for permission to import new drug  122 B - Application for approval to manufacture new drug  122 D -Permission to import or manufacture FDC  122 DA- Permission to conduct clinical trials for New Drug / Investigational New Drug  122 DAA –Definition Of “CLINICAL TRIAL”  “Clinical trial” - a systematic study of new drug(s) in human subject(s) to generate data for discovering and / or verifying the clinical, pharmacological effect (including pharmacodynamic and pharmacokinetic) and /or adverse effects with the objective of determining safety and / or efficacy of the new drug.
  • 8. 122-E Definition of new drugs Not been used in the country under labeling conditions Approved but now proposed to be marketed with modified or new claims – indications, dosage, dosage form , route of administration , FDC , individually approved to be combined for the first time in a fixed ratio or if ratio is changed
  • 10. It contains data to be submitted along with the application to conduct clinical trials / import / manufacture of new drugs for marketing in the country. 1. Introduction • a. A brief description of the drug and the therapeutic class to which it belongs. 2. Chemical and pharmaceutical information • 2.1 Information on active ingredients Drug information (Generic Name, Chemical Name etc.) Physicochemical Data A. Chemical name and Structure Empirical formula Molecular weight B. Physical properties Solubility Rotation Partition coefficient Dissociation constant
  • 11. 2.3 Analytical Data Elemental analysis Mass spectrum NMR spectra IR spectra UV spectra Polymorphic identification 2.4 Complete monograph specification including Identification Identity/quantification of impurities Enantiomeric purity Assay 2.5 validation 2.6 stability studies ( for details refer appendix IX)
  • 12. 3.Animal pharmacology (for details refer appendix IV)  Summary  Specific pharmacological actions  General pharmacological actions  Follow-up and Supplemental Safety Pharmacology Studies  Pharmacokinetics: absorption, distribution; metabolism; excretion 2.7 data on formulation • dosage form, •composition, •master manufacturing formula, •In process quality control check, •Excipients compatibility study •Finished product specification •Validation of the analytical method
  • 13. 4. Animal toxicology (for detail refer appendix IV) General Aspects Systemic Toxicity Studies Male Fertility Study Female Reproduction and Developmental Toxicity Studies Local toxicity Allergenicity/Hypersensitivity Genotoxicity Carcinogenicity
  • 14. 5. Human/clinical pharmacology (phase I) •Summary •Specific Pharmacological effects •General Pharmacological effects •Pharmacokinetics, absorption, distribution, metabolism, excretion •Pharmacodynamics /early measurement of drug activity
  • 15. 6. Therapeutic exploratory trial (phase II) •Summary •Study report(s) as given in Appendix II 7. Therapeutic confirmatory trial (phase III) •Summary •Individual study reports with listing of sites and Investigators. 8. Special studies Summary Bio-availability / Bio-equivalence. Study on special group of population e.g. geriatrics, pediatrics , pregnant or nursing women
  • 16. Geriatrics •Geriatric patients should be included in Phase III clinical trials (and in Phase II trials, at the Sponsor's option) in meaningful numbers, •If the disease intended to be treated is characteristically a disease of aging; or the population to be treated is known to include substantial numbers of geriatric patients;
  • 17. The pediatric studies should include - clinical trials, relative bioequivalence comparisons of the pediatric formulation with the adult formulation performed in adults definitive pharmacokinetic studies for dose selection across the age ranges of pediatric patients in whom the drug is likely to be used. These studies should be conducted in the pediatric patient population with the disease under study The timing of pediatric studies in the new drug development program will depend on the medicinal product, the type of disease being treated, safety considerations, and the efficacy and safety of available treatments. Pediatrics
  • 18. Pregnant or Nursing Women •Pregnant or nursing women should be included in clinical trials only when the drug is intended for use by pregnant/nursing women or fetuses/nursing infants and where the data generated from women who are not pregnant or nursing, is not suitable. •For new drugs intended for use during pregnancy, follow-up data (pertaining to a period appropriate for that drug) on the pregnancy, fetus and child will be required.
  • 19. 9. Regulatory status in other countries 9.1 countries where the drug is a. marketed b. Approved c. approved as IND d. withdrawn, if any , with reason 9.2 restriction use, if any , in countries where marketed/ approved 9.3 free sale certificate or certificate of analysis , as appropriate. 10. Prescribing information 10.1 proposed full prescribing information 11. Samples and testing protocol NOTE : All items may not be applicable to all drugs. For explanation, refer text of Schedule Y. •For requirements of data to be submitted with application for clinical trials we should refer text of this Schedule
  • 20.  Data required to be submitted by an applicant for grant of permission to import and/or manufacture a new drug already approved in the country  Introduction ( About the drug and its therapeutic class)  Chemical and pharmaceutical information (Chemical name, Generic name, Structure , Physico chemical properties)  Marketing information (Promotional literature)  Special studies conducted with approval of licensing authority ◦ Bioavailability/ Bioequivalance and comparative dissolution studies for oral dosage forms ◦ Sub acute animal toxicity studies for intravenous infusions and injectables.
  • 21.  1. Title page :- title of the study, the protocol code, name of the investigational product tested, development phase, indication studied, a brief description page, the start and end date of patient accrual and the names of the sponsor and the participating institute  2. Study synopsis(1 to 2 pages) :- a brief review of study from the protocol development to the trial closure should be given here. This section will only summarize the important conclusions derived from the study  3. statement of compliance  4.list of abbreviation and definitions  Table of contents
  • 22.  6. ethics committee:  7.study team  8.study objective  9.investigational plan  Trial subjects  Efficacy evaluation  Safety evaluation  Discussion and overall conclusion  List of references  appendices
  • 23. ANIMAL TOXICOLOGY (NON-CLINICAL TOXICITY STUDIES) • Acute toxicity • Long-term toxicity  Reproduction studies • Fertility studies • Teratogenicity studies:  Local toxicity:  Mutagenicity and Carcinogenicity  Application Of Good Laboratory Practices (GLP)
  • 24. Animal pharmacology  General Principles ◦ Specific and general pharmacological studies should be conducted to support the use of therapeutics in human ◦ Safety pharmacological studies investigates potential undesirable pharmacodynamic effect of as substance on physiological function in relation to exposer within the therapeutic range or above.  Specific Pharmacological Actions  Are those which demonstrate the therapeutic potential for humans.  General pharmacological Actions  Essential Safety Pharmacology  To study the effect of the test drug on vital functions such as cardiovascular, respiratory and central nervous system are studied
  • 25.  Supplemental Safety Pharmacology Studies Investigation of the adverse pharmacological effect that are not assessed in the in the essential safety pharmacological studies and are a cause for concern  Urinary System Includes urine volume, specific gravity , osmolality, pH , proteins, cytology, and blood urea nitrogen , creatinine , plasma protein estimation .  Autonomic Nervous System Binding to receptor relevant to ANS and functional response to agonist or antagonist responses in in vitro or in vivo.  Gastrointestinal System Studies of gastric secretion, gastric pH, bile secretion, gastric emptying time etc Other Organ Systems
  • 26.  Trial involves research  Purpose  Trial treatment and randomization  Trial procedures  Risk  Benefit  Alternative treatments  Compensation /treatment for injury  Subject responsibilities  Experiment aspects  Any payment
  • 27.  Confidentiality  New information  Voluntary participation  Persons to contact for study information  Rights of subjects, if study related injury  Reasons for termination  Duration of study  Number of subjects  Any other pertinent information
  • 28.  Study title  Subject initials e.g. subjects name/date of birth/age  Consent statement with initials in  A) signature of the subject  B) Legally acceptable representative  Signature of the investigator  Study investigators name  Signature of the witness  Name of the witness
  • 29. Combination therapy with two or more agents having complementary mechanism of action is an example of incremental innovation that may extend the range of therapeutic options in the treatment of almost every human disease Fixed dose combination(FDC) fall into four categories A. one or more of the active ingredients is a new drugs B. First time combination of individually approved/marketed drugs, where the ingredients are likely to have significant interaction of a pharmacodynamic or pharmacokinetic nature C. Combination already marketed, but in which it is proposed either to change the ratio of active ingredients or to make new therapeutic claim D. Combined only for the purpose of convenience
  • 30. 1. - Full name - Address - Title of Principal Investigator (or Investigator if no PI) 2. -Name & Address of the medical college, hospital or facility. - Education training & experience of the Investigator 3. Name & address of all clinical laboratory facilities 4. Name and address of EC 5. Name of other members of the research team 6. Protocol title & Study number (if any) 7. Commitments 8. Signature of the Investigator with Date.
  • 31. Appendix VIII - ETHICS COMMITTEE •It should have at least seven members . • a chair person (who is from outside the institution) and a member secretary •Other member should be mix of medical/ non-medical scientific/ non-scientific persons including lay public , to reflect their different view point •The quorum of ethics committee should have at least 5 members •Basic medical scientist( pharmacologist) •Clinician •Legal expert •Social scientist/ethicist/philosopher etc. •Lay person from the community NOTE : ONLY THOSE ETHICS COMMITTEE MEMBER WHO ARE INDEPENDENT OF THE CLINICAL TRIAL AND THE SPONSOR OF THE TRIAL SHOULD VOTE / PROVIDE OPINION IN MATTERS RELATED TO STUDY .
  • 32.  Stability testing is to be performed to provide evidence on how the quality of the drug substance or formulation varies with time under influence of environmental factors such as temperature , humidity , and light , and to establish shelf life for the formulation and recommended storage condition  It includes testing of those attributes of the drug that are susceptible to change during storage and are likely to influence quality , safety and / or efficacy .
  • 33.  Title page ◦ Full title of the clinical study ◦ Protocol/study number and protocol version number with date ◦ The Investigational New Drug (IND) name/number of the investigational drugs ◦ Complete name and address of the sponsor and contract research organization if any ◦ List of the investigators who are conducting the study ◦ Names of clinical laboratories and other departments and/ or facilities participating in the studies  Table of content ◦ A complete table of content including a list of all appendices 1. Background and Introduction a. Preclinical experiences b. Clinical experiences
  • 34. 2 . Study rationale This section should describe a brief summary of the background information relevant to the study design and protocol methodology 3. Study design a. Overview of the study design b. Flowchart of the study c. A brief description of the methods and procedure used during the study 4. Study population the number of subject required to be enrolled in the study at the investigative site and by all site along with a brief description of the nature of the subject population required is also mentioned 5.Subject eligibility a. Inclusion criteria b. Exclusion criteria
  • 35. 6. Study treatment: Dosing schedule , details of product stability, storage requirements , dispensing requirements, possible drug interactions 7. Adverse events: Description of expected adverse events should be given 8. Data analysis 9. Undertaking by the investigator (appendix VII) NOTE- protocol is assigned by sponsor after getting CDA from investigator
  • 36. 1. Patient details  Initials & other relevant identifier (hospital/ OPD record number etc)  Gender  Age &/or date of birth  Weight  Height 2. Suspected drug(s) - Generic name of the drug - Indication(s) for which suspect drug was prescribed or tested - Dosage form and strength - Daily dose & regimen (specify units-e.g. mg, ml, mg/kg) - Route of administration - Starting date & time of the day - Stopping date and time, or duration of treatment
  • 37. 3. Details of suspected Adverse Drug Reaction(s)  Full Description of reaction(s) including: - body site - severity - criterion for considering the report as serious.  In addition to the description of signs & symptoms whenever possible describe a specific diagnosis for the reaction. - Start date (& time) of onset of reaction - Stop date (& time) of duration of reaction 4. Details about Investigator - Name - Address - Telephone number - Profession (Specialty) - Date of reporting the event to the Licensing Authority - Date of reporting the event to Ethics Committee over seeing the site - Signature of the Investigator
  • 38. “With The Schedule Y The Efforts Are Aligned In a Single Direction To Ensure That Irrespective Of The Country, The Data Generated is Of Good Quality And Standard Which Can Be Accepted World Wide”
  • 39. 1. GUPTA S. K. BASIC PRINCIPLE OF CLINICAL RESEARCH AND METHODOLOGY 2. http://www.slideshare.net/slideshare006/schedule-y-mk- sharma.(date-08.12.2016) 3. http://www.cdsco.nic.in/html/D&C_Rules_Schedule_Y.pdf(11.1 2.2016)